# NKT5097

Source: https://onco.cc/drugs/nkt5097/  
OnCo record `nkt5097` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NKT5097 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for HR-positive breast cancer and CCNE1-amplified solid tumours.

## Summary

NKT5097 is a small molecule degrader, oral from NiKang Therapeutics. A dual degrader of CDK2 and CDK4, cell-cycle enzymes. The phase 1 study NCT07029399 tests it alone and with fulvestrant or letrozole. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: NKT5097
- Modality: Small molecule degrader, oral
- Mechanism: A dual degrader of CDK2 and CDK4, cell-cycle enzymes.

## Sources

- NiKang science and pipeline: https://www.nikangtx.com/science-and-pipeline/
- ClinicalTrials.gov NCT07029399: https://clinicaltrials.gov/study/NCT07029399

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [NiKang Therapeutics](https://onco.cc/companies/nikang-therapeutics/)
- trials: [A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct07029399/)

---
JSON: https://onco.cc/api/v1/entities/nkt5097.json